Targeted protein degradation via intramolecular bivalent glues

Oliver Hsia,Matthias Hinterndorfer,Angus D. Cowan,Kentaro Iso,Tasuku Ishida,Ramasubramanian Sundaramoorthy,Mark A. Nakasone,Hana Imrichova,Caroline Schätz,Andrea Rukavina,Koraljka Husnjak,Martin Wegner,Alejandro Correa-Sáez,Conner Craigon,Ryan Casement,Chiara Maniaci,Andrea Testa,Manuel Kaulich,Ivan Dikic,Georg E. Winter,Alessio Ciulli

DOI: https://doi.org/10.1038/s41586-024-07089-6

IF: 64.8

2024-02-22

Nature

Abstract:Targeted protein degradation is a pharmacological modality that is based on the induced proximity of an E3 ubiquitin ligase and a target protein to promote target ubiquitination and proteasomal degradation. This has been achieved either via proteolysis-targeting chimeras (PROTACs)—bifunctional compounds composed of two separate moieties that individually bind the target and E3 ligase, or via molecular glues that monovalently bind either the ligase or the target 1,2,3,4 . Here, using orthogonal genetic screening, biophysical characterization and structural reconstitution, we investigate the mechanism of action of bifunctional degraders of BRD2 and BRD4, termed intramolecular bivalent glues (IBGs), and find that instead of connecting target and ligase in trans as PROTACs do, they simultaneously engage and connect two adjacent domains of the target protein in cis . This conformational change 'glues' BRD4 to the E3 ligases DCAF11 or DCAF16, leveraging intrinsic target–ligase affinities that do not translate to BRD4 degradation in the absence of compound. Structural insights into the ternary BRD4–IBG1–DCAF16 complex guided the rational design of improved degraders of low picomolar potency. We thus introduce a new modality in targeted protein degradation, which works by bridging protein domains in cis to enhance surface complementarity with E3 ligases for productive ubiquitination and degradation.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a new targeted protein degradation method by using "Intramolecular Bivalent Glues (IBGs)" to achieve the selective degradation of specific proteins such as BRD2 and BRD4. Traditional methods include using PROTACs (Proteolysis - Targeting Chimeras) or monovalent molecular glues. These methods usually need to link the target protein and E3 ubiquitin ligase to promote the ubiquitination of the target protein and the subsequent proteasome degradation. However, IBGs work through different mechanisms. Instead of linking the target and the ligase at the transcriptional level like PROTACs, they simultaneously bind and link two adjacent domains of the target protein, thereby changing its conformation, making the target protein (for example, BRD4) form a tighter interaction with E3 ligases DCAF11 or DCAF16, and then achieving efficient protein degradation.

The paper describes in detail the discovery process of IBG1 and how it specifically degrades BRD2 and BRD4 by recruiting DCAF16 without affecting BRD3. In addition, the researchers also revealed through structural biology methods how IBG1 simultaneously binds to the two bromodomains of BRD4 and how this binding enhances the affinity between BRD4 and DCAF16. Based on these findings, the research team further designed IBG3, a compound containing two JQ1 groups, which shows a higher degradation efficiency, reaching an activity at the low picomolar level.

In summary, this paper aims to explore and verify a novel protein degradation strategy, that is, to achieve the selective and efficient degradation of specific proteins through intramolecular bivalent glues, which provides new ideas and technical means for the development of new therapeutic drugs.